[doi: 10.5505/2017ichc.PP-122]Insignificant association between megalin expression in prostate cancer tissue and prostate cancer stem cellsGulperi Oktem1, Gunel Mukhtarova2, Cuneyd Parlayan3, Sule Ayla4, Asli Cakir5, Selcuk Guven62Department of Stem Cell, Health Science Institute, Ege University, Izmir, Turkey, 3Department of Biomedical Engineering, School of Engineering and Natural Science, Istanbul Medipol University, Istanbul, Turkey 4Department of Histology and Embryology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey 5Department of Pathology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey 6Department of Urology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey Introduction & OBJECTIVES: An endocytic multiligand receptor megalin (LRP2, low density lipoprotein-related protein 2) is a transmembrane protein of approximately 600 kDa (encoded by LRP2) that known to mediate uptake and trafficking of of a vast number of ligands: nutrients including vitamin carriers (e.g., of vitamin B12 and vitamin D), apolipoproteins, albumin and signaling molecules. Megalin also known to modulate the signaling of sonic hedgehog (SHH), epidermal growth factor (EGF), and insulin-like growth factor-1 (IGF-1). Megalin expressed by prostate epithelial cells. In cancer tissue and cell also have been shown increased megalin expression. This increased megalin expression provide more uptake of the nutrient and signal molecules in the rapidly growing cancer cells that show an increased demand for nutrients. The aim of our study was to investigate megalin expression in prostate cancer tissue sample and prostate cancer cell line, to compare expression levels with patient clinical data and to explore potential associations with disease risk, recurrence/ progression, prostate-specific mortality, and possible interactions with primary ADT in hospital base study for the understand a role of megalin in tumor progression. Materials & METHODS: Primary tumors (n = 92) were stained with megalin antibodies using immunohistochemistry and compared expression levels with clinical data. We analysed gene expression profiles of megalin in prostate cancer stem cell (Du145 CSC) comparatively to non-CSC (Du145 non-CSC), prostate cancer cell line (Du145 cell line) and prostate epithelial cell line (RWPE1 cell line). Whole transcriptome sequencing was done on relevant experimental groups. RESULTS: İn result immunohistochemical assay and transcriptom sequencing analysis we did not find significantly correlation beetwen megalin ekspression in patient sample tissue and prostate cancer cell line, prostate cancer stem cell line with patient clinical date CONCLUSION: In conclusion, while, our finding did not support a role of megalin in tumor progression for the robustness of our results may reqiure larger study that include analisys of genetic variation within LRP2 gene and alternative splicing during LRP2 gene expression. |